Video

Dr. Rudin on Significance of the KEYNOTE-021 in Patients With NSCLC

Charles M. Rudin, MD, PhD, chief, Thoracic Oncology Service, co-director, Druckenmiller Center for Lung Cancer Research, Sylvia Hassenfeld Chair in Lung Cancer Research, Memorial Sloan Kettering Cancer Center, discusses the caveats of KEYNOTE-021.

Charles M. Rudin, MD, PhD, chief, Thoracic Oncology Service, co-director, Druckenmiller Center for Lung Cancer Research, Sylvia Hassenfeld Chair in Lung Cancer Research, Memorial Sloan Kettering Cancer Center, discusses the caveats of the KEYNOTE-021 trial.

KEYNOTE-021 cohort G was one arm of a very large trial that enrolled patients with previously untreated metastatic non—small cell lung cancer (NSCLC). That study was the first to look at the role of first-line chemotherapy plus immunotherapy for NSCLC. The results suggested that chemotherapy with immune-oncology drugs was better than chemotherapy alone.

Some of the caveats of the trial are that it was a small trial that was powered to look at survival. The progression-free survival curves seemed to favor the immunotherapy arm, but the trials were really designed with a primary endpoint of response rate. Ultimately, the phase III data need to be seen before it can be established as a standard of care, says Rudin.

Related Videos
David Samuel Dicapua Siegel, MD
Axel Hauschild, MD, PhD, head, Skin Cancer Trial Center, University Hospital Schleswig-Holstein
 Philip McCarthy, MD
Lova L. Sun, MD, MSCE
Robert M. Rifkin, MD, FACP
Ahmad Tarhini, MD, PhD
Allison Winter, MD
Rocio Garcia-Carbonero, MD
Andrew Ip, MD
Anthony B. El-Khoueiry, MD